Trial · NCT06618820
Extended Oral Tranexamic Acid After Total Knee Arthroplasty
NCT06618820, Phase 3, Enrolling by invitation, Campbell Clinic
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Extended Oral Tranexamic Acid After Total Knee Arthroplasty. Trials, record NCT06618820. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06618820
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Extended Oral Tranexamic Acid After Total Knee Arthroplasty
- NCT number
- NCT06618820
- Status
- Enrolling by invitation
- Phases
- Phase 3
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Campbell Clinic
- Conditions
- Osteo Arthritis Knee, Pain, Postoperative
- Interventions
- Tranexamic acid, Placebo
- First posted
- 2024-10-01
- Last updated
- 2026-08-13
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Forgotten Joint Score - Knee | Enrollment; 2-week postoperative; 6-week postoperative; 12-week postoperative; 1-year postoperative. | The Forgotten Joint Score measures how much the patient is aware of their affected knee during activities of daily living. A score of 0 indicates that the patient is always aware of their affected knee whereas a score of 100 indicates that the patient is not aware of their affected knee during activities of daily living. |
| Primary | Range of Motion | Enrollment; 2-week postoperative; 6-week postoperative; 12-week postoperative; 1-year postoperative. | Passive flexion and extension range of motion of the surgical knee will be assessed with a goniometer in degrees. |
| Secondary | Knee Injury and Osteoarthritis Outcome Score for Joint Replacement | Enrollment; 2-week postoperative; 6-week postoperative; 12-week postoperative; 1-year postoperative. | This questionnaire assesses patients' knee health with 0 representing total disability and 100 represents perfect knee health. |
| Secondary | Patient-Reported Outcomes Measurement Information System | Enrollment; 2-week postoperative; 6-week postoperative; 12-week postoperative; 1-year postoperative. | This questionnaire assesses patients' overall health and wellbeing with a T-score of 16.2 representing most severe physical impairment and a T-score of 67.7 represents best possible state of health. |
| Secondary | Visual Analog Scale | Enrollment; postoperative day 1 to postoperative day 14; 2-week postoperative; 6-week postoperative; 12-week postoperative; 1-year postoperative. | This questionnaire assesses patient's pain level with 0 being no pain at all and 10 being worst pain possible. |
| Secondary | Opiate pill count | postoperative day 1 to postoperative day 14; 2-week postoperative; 6-week postoperative; 12-week postoperative; 1-year postoperative. | The investigators will record the number of opiate medication taken by the patient and calculate morphine milligram equivalents. |
| Secondary | Ambulatory aid | Enrollment; postoperative day 1 to postoperative day 14; 2-week postoperative; 6-week postoperative; 12-week postoperative; 1-year postoperative. | The investigators will record the use of ambulatory aid, such as walker. |
| Secondary | Adverse Event | From signing consent form to completion of 1 year follow up visit. | The investigators will monitor for adverse events, including but not limited to deep venous thrombosis, and pulmonary embolism. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06618820
GET https://conductscience.org/api/trials/v1/NCT06618820/registered